PRED MILD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRED MILD (PRED MILD).
Prednisolone acetate is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2 and reduction of inflammatory mediators such as prostaglandins and leukotrienes.
| Metabolism | Primarily hepatic via CYP3A4; major metabolite is prednisolone (active form of prednisone). |
| Excretion | Prednisolone is primarily excreted renally, with approximately 70-80% of the dose eliminated as metabolites in urine (including glucuronides and sulfates) and less than 10% as unchanged drug. Biliary/fecal excretion accounts for about 20% of the dose. |
| Half-life | The terminal elimination half-life of prednisolone is approximately 2.1-3.5 hours. Clinically, this short half-life supports once-daily dosing for many conditions, with minimal accumulation upon repeated administration. |
| Protein binding | Prednisolone is approximately 70-90% bound to plasma proteins, primarily to corticosteroid-binding globulin (CBG) and, to a lesser extent, albumin. |
| Volume of Distribution | The volume of distribution (Vd) of prednisolone is approximately 0.4-0.6 L/kg. This suggests moderate distribution into tissues, with a Vd approximately equal to total body water, indicating not extensive tissue binding. |
| Bioavailability | Oral bioavailability of prednisolone is approximately 70-80%. This high bioavailability is due to its rapid and nearly complete absorption from the gastrointestinal tract. |
| Onset of Action | Oral: Onset of action occurs within 1-2 hours; intravenous: within minutes to 1 hour; topical: onset varies by formulation, typically within a few days for dermatological effects. |
| Duration of Action | Oral: Duration of action is typically 18-36 hours, as measured by adrenal suppression and anti-inflammatory effects, despite the short half-life. Topical: Duration depends on formulation and site, generally requiring once or twice daily application. |
1 to 2 drops in the affected eye(s) every hour during the day and every 2 hours at night until a favorable response is obtained, then reduce to 1 drop every 4 hours, and later to 1 drop 3 to 4 times daily as needed to control symptoms.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. Use only if potential benefit outweighs risk. |
| Geriatric use | No specific dose adjustment recommended, use with caution due to increased risk of intraocular pressure elevation and cataract formation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRED MILD (PRED MILD).
| Breastfeeding | Prednisolone enters breast milk in low amounts. M/P ratio not established for ophthalmic formulation; systemic prednisolone M/P ratio is approximately 0.4-0.6. Topical ocular use results in negligible systemic absorption; risk to infant is considered minimal. Compatible with breastfeeding. |
| Teratogenic Risk | First trimester: Increased risk of orofacial clefts (odds ratio 1.3-3.4) with systemic use; no data for topical prednisolone acetate 0.12% (PRED MILD) due to negligible systemic absorption. Second/third trimesters: Risk of fetal adrenal suppression with prolonged high-dose systemic corticosteroids, but not expected with topical ophthalmic use. Overall risk considered low based on minimal systemic exposure. |
■ FDA Black Box Warning
None
| Serious Effects |
["Uncontrolled ocular infections (e.g., fungal, viral, bacterial, or mycobacterial)","Known hypersensitivity to prednisolone or any component."]
| Precautions | ["Prolonged use may lead to cataracts, glaucoma, secondary ocular infections, and delayed wound healing.","Use caution in patients with corneal thinning.","Avoid abrupt discontinuation after long-term use."] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. For high-dose or prolonged systemic use (not typical for ophthalmic), monitor for signs of adrenal suppression in the neonate (e.g., hypoglycemia, hypotension). |
| Fertility Effects | No adverse effects on fertility reported with topical ophthalmic corticosteroids. Systemic corticosteroids may impair fertility by inhibiting ovulation or spermatogenesis, but this is not relevant for PRED MILD due to minimal systemic absorption. |